Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29258756 | 0.85 | ATR (0.41) | KCNN4SMN1; SMN2CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL2816857 | 0.85 | LMNA (0.42) | KCNN4SLC6A2SLC6A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL29258348 | 0.81 | L3MBTL1 (0.37) | SMN1; SMN2CYP4F2CYP4A11ALDH1A1HSD11B1 | |
| SCHEMBL3396469 | 0.80 | ATR (0.33) | KCNN4SMN1; SMN2CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL26772018 | 0.76 | CYP4F2 (0.48) | CYP4F2CYP4A11ATR | |
| SCHEMBL30955463 | 0.72 | PTPN11 (0.42) | SLC6A2SLC6A4CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL30955445 | 0.71 | BRD4 (0.39) | CYP4F2CYP4A11ALDH1A1POLBATR | |
| SCHEMBL30955476 | 0.70 | PTPN11 (0.42) | CYP4F2CYP4A11ATR | |
| SCHEMBL19879311 | 0.70 | ATR (0.37) | CYP4F2CYP4A11PDE10AATR | |
| SCHEMBL19866178 | 0.70 | RET (0.39) | CYP4F2CYP4A11PDE10AATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2246348-A1 | Coupling reactions useful in the preparation of (1h-tetrazol-5-yl)-biphenyl derivatives | Novartis AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-20100249429-A1 | PROCESS FOR THE MANUFACTURE OF VALSARTAN | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-09-30 | — | — | US | disclosed |
| US-20100152458-A1 | COUPLING REACTIONS USEFUL IN THE PREPARATION OF (1H-TETRAZOL-5-YL) BIPHENYL DERIVATIVES | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| US-7700784-B2 | Coupling reactions useful in the preparation of (1h-tetrazol-5-yl) biphenyl derivatives | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-20090111995-A1 | Process for the manufacture valsartan | NOVARTIS AG (CH) | 2009-04-30 | — | — | US | disclosed |
| EP-1546122-B8 | PROCESS FOR THE MANUFACTURE OF VALSARTAN | NOVARTIS AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| EP-1878729-A1 | INTERMEDIATE FOR THE MANUFACTURE OF VALSARTAN | Novartis AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| US-20070129413-A1 | Coupling reactions useful in the preparation of (1h-tetrazol-5-yl) biphenyl derivatives | NOVARTIS PHARMACEUTICALS CORPORATION | 2007-06-07 | — | — | US | disclosed |
| EP-1716140-A1 | COUPLING REACTIONS USEFUL IN THE PREPARATION OF (1H-TETRAZOL-5-YL)-BIPHENYL DERIVATIVES | Novartis AG (CH) | 2006-11-02 | — | — | EP | disclosed |
| US-20060069268-A1 | Process for the manufacture of valsartan | DENNI-DISCHERT DONATIENNE | 2006-03-30 | — | — | US | disclosed |
| WO-2005075462-A1 | COUPLING REACTIONS USEFUL IN THE PREPARATION OF (1H-TETRAZOL-5-YL)-BIPHENYL DERIVATIVES | NOVARTIS AG (CH) | 2005-08-18 | — | — | WO | disclosed |
| EP-1546122-A1 | PROCESS FOR THE MANUFACTURE OF VALSARTAN | Novartis AG (CH) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004026847-A1 | PROCESS FOR THE MANUFACTURE OF VALSARTAN | NOVARTIS AG (CH) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152458-A1 | COUPLING REACTIONS USEFUL IN THE PREPARATION OF (1H-TETRAZOL-5-YL) BIPHENYL DERIVATIVES | AGTR1, AGTR2, AGT | KCNN4 2789/4885SLC6A2 1392/4885SLC6A4 1321/4885 |
| US-20070129413-A1 | Coupling reactions useful in the preparation of (1h-tetrazol-5-yl) biphenyl derivatives | AGTR1, AGTR2, AGT | KCNN4 2943/4885SLC6A2 1437/4885SLC6A4 1433/4885 |
| US-20060069268-A1 | Process for the manufacture of valsartan | AGTR1, AGTR2, AGT | KCNN4 1925/4885SLC6A2 355/4885SLC6A4 598/4885 |
| US-20100249429-A1 | PROCESS FOR THE MANUFACTURE OF VALSARTAN | AGTR1, AGTR2, AGT | KCNN4 1925/4885SLC6A2 355/4885SLC6A4 598/4885 |
| US-20090111995-A1 | Process for the manufacture valsartan | AGTR1, AGTR2, AGT | KCNN4 2395/4885SLC6A2 367/4885SLC6A4 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.